The 10 year agreement with Wockhardt in India initially covers: Atopiclair – non steroidal cream for atopic dermatitis, Aloclair – presentations for the treatment of mouth ulcers, Papulex – presentations for the treatment of acne and Decapinol – product range for the treatment and prevention of gingivitis and plaque.
Under the agreement Sinclair will provide finished product to Wokhardt but switch to local manufacture as soon as possible, which will enhance the margins for Sinclair. This agreement is said to be a further step towards Sinclair’s goal of establishing its brands in the key BRIC (Brazil, Russia, India and China) countries.
Michael Flynn, CEO of Sinclair Pharma, said: “We are very pleased to appoint Wockhardt as our distributor for these products in India. We have a very active program pursuing opportunities in the BRIC countries and the Middle East which we believe offer substantial growth opportunities for the sales of our products in the coming years.”